TELA Bio, Inc. provided earnings guidance for the three months ended March 31, 2023. For the period, the company estimated revenue to be $11.9 million, compared to $8.2 million over the corresponding period of 2022.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.315 USD | +0.56% | +8.25% | -4.83% |
05-10 | Piper Sandler Adjusts Price Target on TELA Bio to $10 From $12, Maintains Overweight Rating | MT |
05-09 | Earnings Flash (TELA) TELA BIO Posts Q1 Revenue $16.6M, vs. Street Est of $16.3M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.83% | 155M | |
-6.32% | 180B | |
+3.07% | 112B | |
-2.92% | 68.53B | |
+5.00% | 51.97B | |
+6.34% | 44.08B | |
+5.62% | 42.23B | |
+23.47% | 32.43B | |
+16.72% | 26.39B | |
-3.02% | 24.97B |
- Stock Market
- Equities
- TELA Stock
- News TELA Bio, Inc.
- TELA Bio, Inc Provides Earnings Guidance for the Three Months Ended March 31, 2023